866-997-4948(US-Canada Toll Free)

Squamous Non-Small Cell Lung Cancer - Pipeline Review, H1 2013

Published By :

Global Markets Direct

Published Date : Feb 2013

Category :

Cancer

No. of Pages : 60 Pages


Global Markets Directs, \'Squamous Non-Small Cell Lung Cancer Pipeline Review, H1 2013\', provides an overview of the indications therapeutic pipeline. This report provides information on the therapeutic development for Squamous Non-Small Cell Lung Cancer, complete with latest updates, and special features on late-stage and discontinued projects. It also reviews key players involved in the therapeutic development for Squamous Non-Small Cell Lung Cancer. 

Squamous Non-Small Cell Lung Cancer Pipeline Review, Half Year is built using data and information sourced from Global Markets Directs proprietary databases, Company/University websites, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources, put together by Global Markets Directs team.

Note*: Certain sections in the report may be removed or altered based on the availability and relevance of data for the indicated disease.

Scope
  • A snapshot of the global therapeutic scenario for Squamous Non-Small Cell Lung Cancer.
  • A review of the Squamous Non-Small Cell Lung Cancer products under development by companies and universities/research institutes based on information derived from company and industry-specific sources.
  • Coverage of products based on various stages of development ranging from discovery till registration stages.
  • A feature on pipeline projects on the basis of monotherapy and combined therapeutics.
  • Coverage of the Squamous Non-Small Cell Lung Cancer pipeline on the basis of route of administration and molecule type.
  • Key discontinued pipeline projects.
  • Latest news and deals relating to the products.

Reasons to buy

  • Identify and understand important and diverse types of therapeutics under development for Squamous Non-Small Cell Lung Cancer.
  • Identify emerging players with potentially strong product portfolio and design effective counter-strategies to gain competitive advantage.
  • Plan mergers and acquisitions effectively by identifying players of the most promising pipeline.
  • Devise corrective measures for pipeline projects by understanding Squamous Non-Small Cell Lung Cancer pipeline depth and focus of Indication therapeutics.
  • Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope.
  • Modify the therapeutic portfolio by identifying discontinued projects and understanding the factors that drove them from pipeline.
Table of Contents

Table of Contents 2

List of Tables 4
List of Figures 5
Introduction 6
Global Markets Direct Report Coverage 6
Squamous Non-Small Cell Lung Cancer Overview 7
Therapeutics Development 8
An Overview of Pipeline Products for Squamous Non-Small Cell Lung Cancer 8
Squamous Non-Small Cell Lung Cancer Therapeutics under Development by Companies 10
Squamous Non-Small Cell Lung Cancer Therapeutics under Investigation by Universities/Institutes 11
Late Stage Products 12
Comparative Analysis 12
Mid Clinical Stage Products 13
Comparative Analysis 13
Early Clinical Stage Products 14
Comparative Analysis 14
Squamous Non-Small Cell Lung Cancer Therapeutics - Products under Development by Companies 15
Squamous Non-Small Cell Lung Cancer Therapeutics - Products under Investigation by Universities/Institutes 16
Companies Involved in Squamous Non-Small Cell Lung Cancer Therapeutics Development 17
Bristol-Myers Squibb Company 17
F. Hoffmann-La Roche Ltd. 18
Sanofi-Aventis 19
Eli Lilly and Company 20
Eisai Co., Ltd. 21
Pfizer Inc. 22
Axelar AB 23
Squamous Non-Small Cell Lung Cancer - Therapeutics Assessment 24
Assessment by Monotherapy Products 24
Assessment by Combination Products 25
Assessment by Route of Administration 26
Assessment by Molecule Type 28
Drug Profiles 30
lenvatinib - Drug Profile 30
Product Description 30
Mechanism of Action 30
R&D Progress 30
necitumumab - Drug Profile 32
Product Description 32
Mechanism of Action 32
R&D Progress 32
onartuzumab - Drug Profile 34
Product Description 34
Mechanism of Action 34
R&D Progress 34
iniparib - Drug Profile 36
Product Description 36
Mechanism of Action 36
R&D Progress 36
AXL-1717 - Drug Profile 38
Product Description 38
Mechanism of Action 38
R&D Progress 38
ipilimumab + [carboplatin] + [paclitaxel] - Drug Profile 40
Product Description 40
Mechanism of Action 40
R&D Progress 40
necitumumab + [cisplatin] + [pemetrexed disodium] - Drug Profile 42
Product Description 42
Mechanism of Action 42
R&D Progress 42
necitumumab + [cisplatin] + [gemcitabine hydrochloride] - Drug Profile 44
Product Description 44
Mechanism of Action 44
R&D Progress 44
cixutumumab + [cisplatin] + [pemetrexed disodium] - Drug Profile 46
Product Description 46
Mechanism of Action 46
R&D Progress 46
axitinib + [cisplatin] + [gemcitabine] - Drug Profile 48
Product Description 48
Mechanism of Action 48
R&D Progress 48
AXL1717 + Gemcitabine Hydrochloride + Carboplatin - Drug Profile 50
Product Description 50
Mechanism of Action 50
R&D Progress 50
fulvestrant + [gefitinib] - Drug Profile 52
Product Description 52
Mechanism of Action 52
R&D Progress 52
fulvestrant + [erlotinib hydrochloride] - Drug Profile 53
Product Description 53
Mechanism of Action 53
R&D Progress 53
Squamous Non-Small Cell Lung Cancer Therapeutics - Drug Profile Updates 54
Squamous Non-Small Cell Lung Cancer - Product Development Milestones 58
Featured News & Press Releases 58
Sep 13, 2012: Oncolytics Biotech Meets Primary Endpoint For First Stage Of US Phase II Squamous Cell Lung Cancer Clinical Trial 58

Appendix 59
Methodology 59
Coverage 59
Secondary Research 59
Primary Research 59
Expert Panel Validation 59
Contact Us 60
Disclaimer 60

List of Table


Number of Products Under Development for Squamous Non-Small Cell Lung Cancer, H1 2013 8
Products under Development for Squamous Non-Small Cell Lung Cancer - Comparative Analysis, H1 2013 9
Number of Products under Development by Companies, H1 2013 10
Number of Products under Investigation by Universities/Institutes, H1 2013 11
Comparative Analysis by Late Stage Development, H1 2013 12
Comparative Analysis by Mid Clinical Stage Development, H1 2013 13
Comparative Analysis by Early Clinical Stage Development, H1 2013 14
Products under Development by Companies, H1 2013 15
Products under Investigation by Universities/Institutes, H1 2013 16
Bristol-Myers Squibb Company, H1 2013 17
F. Hoffmann-La Roche Ltd., H1 2013 18
Sanofi-Aventis, H1 2013 19
Eli Lilly and Company, H1 2013 20
Eisai Co., Ltd., H1 2013 21
Pfizer Inc., H1 2013 22
Axelar AB, H1 2013 23
Assessment by Monotherapy Products, H1 2013 24
Assessment by Combination Products, H1 2013 25
Assessment by Stage and Route of Administration, H1 2013 27
Assessment by Stage and Molecule Type, H1 2013 29
Squamous Non-Small Cell Lung Cancer Therapeutics - Drug Profile Updates 54

List of Chart


Number of Products under Development for Squamous Non-Small Cell Lung Cancer, H1 2013 8
Products under Development for Squamous Non-Small Cell Lung Cancer - Comparative Analysis, H1 2013 9
Products under Development by Companies, H1 2013 10
Products under Investigation by Universities/Institutes, H1 2013 11
Late Stage Products, H1 2013 12
Mid Clinical Stage Products, H1 2013 13
Early Clinical Stage Products, H1 2013 14
Assessment by Monotherapy Products, H1 2013 24
Assessment by Combination Products, H1 2013 25
Assessment by Route of Administration, H1 2013 26
Assessment by Stage and Route of Administration, H1 2013 27
Assessment by Molecule Type, H1 2013 28
Assessment by Stage and Molecule Type, H1 2013 29

Make an enquiry before buying this Report

Please fill the enquiry form below.

  • Full Name *
  • Your Email *
  • Job Title *
  • Company *
  • Phone No. * (Pls. Affix Country Code)
  • Message
  • Security Code *